SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it intends to offer and sell, subject to market and other conditions, units consisting of shares of its common stock and, in lieu of […]
Category Archives: Pr Newswire
▶ Participates in economic delegation and explores ways to expand bilateral cooperation at the Korea–Philippines Business Forum▶ Pays tribute at Korean War Memorial… Inspects HD Hyundai Philippines Shipyard and encourages local employees▶ HD Hyundai Heavy Industries contributes to Philippine naval modernization with orders for 12 naval vessels and establishment of a logistics support center SEOUL, […]
XIAMEN, China, March 5, 2026 /PRNewswire/ — In January 2026, Xiamen C&D Inc. (stock code: 600153.SH) officially released its 2026–2030 strategic plan for its supply chain operations. Over the next five years, the company will focus on three strategic goals: improving economic efficiency, strengthening market position, and expanding overseas scale. It will also enhance five core […]
LAS VEGAS, March 6, 2026 /PRNewswire/ — LiuGong (000528.SZ) presented 13 machines across multiple product lines at CONEXPO-CON/AGG 2026 under the theme “Tough Customers. Tough Equipment,” covering applications from urban construction to quarrying, mining, and large-scale infrastructure projects. Group Photo at LiuGong Booth, CONEXPO 2026 Electric Solutions for Lower Operating Costs Among the featured machines were […]
MELBOURNE, Australia, March 6, 2026 /PRNewswire/ — As cyber threats intensify and AI adoption accelerates, governance has moved firmly into the boardroom. To address this shift, LRQA, a leading global assurance provider, recently brought together senior executives and risk leaders in Melbourne for a strategic roundtable: “Navigating Cybersecurity and AI Governance: Insights from ISO Standards.” AI […]
Eight New Hospitality Clients Drive Upward Revision to 2026 Hong Kong Revenue Estimate SINGAPORE, March 6, 2026 /PRNewswire/ — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group” or the “Company”), a global leader in on-demand workforce solutions and integrated facilities management (IFM), today announced a significant expansion of its operational footprint in Hong Kong. Following […]
Pr Newswire
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
05
Mar
Mar
Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter 2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025 Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, […]
Pr Newswire
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
05
Mar
Mar
Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital, Dr. Mina strengthens Invivyd’s medical leadership Dr. Mina’s research at Harvard focused on antibodies, vaccines, and infectious diseases with special expertise in COVID-19, measles, and other […]
Pr Newswire
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
05
Mar
Mar
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients […]
05
Mar
Mar
Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP earnings* of $0.24 per diluted share Fourth quarter cash from operations of $38.0 million increased 97% 2026 financial guidance reflects continued above-market revenue growth, higher […]